nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—ABCB1—esophageal cancer	0.273	1	CbGaD
Aripiprazole—HTR3A—vagus nerve—esophageal cancer	0.0138	0.146	CbGeAlD
Aripiprazole—HTR7—vagus nerve—esophageal cancer	0.00894	0.0941	CbGeAlD
Aripiprazole—HTR2A—vagus nerve—esophageal cancer	0.00558	0.0587	CbGeAlD
Aripiprazole—CHRM3—exocrine gland—esophageal cancer	0.00322	0.0339	CbGeAlD
Aripiprazole—H1F0—neck—esophageal cancer	0.00318	0.0335	CbGeAlD
Aripiprazole—CHRM5—epithelium—esophageal cancer	0.00251	0.0264	CbGeAlD
Aripiprazole—H1F0—bronchus—esophageal cancer	0.00213	0.0224	CbGeAlD
Aripiprazole—H1F0—smooth muscle tissue—esophageal cancer	0.00208	0.0219	CbGeAlD
Aripiprazole—HTR7—neck—esophageal cancer	0.00196	0.0206	CbGeAlD
Aripiprazole—H1F0—trachea—esophageal cancer	0.00191	0.0201	CbGeAlD
Aripiprazole—H1F0—digestive system—esophageal cancer	0.00165	0.0173	CbGeAlD
Aripiprazole—ADRB1—bronchus—esophageal cancer	0.0016	0.0169	CbGeAlD
Aripiprazole—HTR3A—digestive system—esophageal cancer	0.00157	0.0165	CbGeAlD
Aripiprazole—HTR2B—smooth muscle tissue—esophageal cancer	0.0015	0.0158	CbGeAlD
Aripiprazole—CHRM1—trachea—esophageal cancer	0.00139	0.0146	CbGeAlD
Aripiprazole—H1F0—lung—esophageal cancer	0.00137	0.0145	CbGeAlD
Aripiprazole—CHRM3—smooth muscle tissue—esophageal cancer	0.00135	0.0142	CbGeAlD
Aripiprazole—HTR7—epithelium—esophageal cancer	0.00133	0.014	CbGeAlD
Aripiprazole—HTR3A—lung—esophageal cancer	0.00131	0.0138	CbGeAlD
Aripiprazole—ADRA1A—epithelium—esophageal cancer	0.00129	0.0136	CbGeAlD
Aripiprazole—HTR7—smooth muscle tissue—esophageal cancer	0.00129	0.0135	CbGeAlD
Aripiprazole—HTR2A—neck—esophageal cancer	0.00122	0.0129	CbGeAlD
Aripiprazole—ADRA2C—bronchus—esophageal cancer	0.00121	0.0127	CbGeAlD
Aripiprazole—SLC6A4—digestive system—esophageal cancer	0.0012	0.0126	CbGeAlD
Aripiprazole—HTR2B—digestive system—esophageal cancer	0.00119	0.0125	CbGeAlD
Aripiprazole—HTR7—trachea—esophageal cancer	0.00118	0.0124	CbGeAlD
Aripiprazole—ADRA2C—trachea—esophageal cancer	0.00108	0.0114	CbGeAlD
Aripiprazole—CHRM3—digestive system—esophageal cancer	0.00107	0.0112	CbGeAlD
Aripiprazole—ADRB1—lung—esophageal cancer	0.00103	0.0109	CbGeAlD
Aripiprazole—HTR7—digestive system—esophageal cancer	0.00102	0.0107	CbGeAlD
Aripiprazole—SLC6A4—lung—esophageal cancer	0.000999	0.0105	CbGeAlD
Aripiprazole—HRH1—epithelium—esophageal cancer	0.000996	0.0105	CbGeAlD
Aripiprazole—CHRM1—lung—esophageal cancer	0.000995	0.0105	CbGeAlD
Aripiprazole—HTR2B—lung—esophageal cancer	0.00099	0.0104	CbGeAlD
Aripiprazole—ADRA2A—bronchus—esophageal cancer	0.000964	0.0101	CbGeAlD
Aripiprazole—HRH1—smooth muscle tissue—esophageal cancer	0.00096	0.0101	CbGeAlD
Aripiprazole—H1F0—lymph node—esophageal cancer	0.00094	0.00989	CbGeAlD
Aripiprazole—HRH1—trachea—esophageal cancer	0.000881	0.00928	CbGeAlD
Aripiprazole—ADRA2A—trachea—esophageal cancer	0.000865	0.00911	CbGeAlD
Aripiprazole—HTR7—lung—esophageal cancer	0.000848	0.00893	CbGeAlD
Aripiprazole—HTR2A—epithelium—esophageal cancer	0.000832	0.00876	CbGeAlD
Aripiprazole—HTR2A—smooth muscle tissue—esophageal cancer	0.000802	0.00844	CbGeAlD
Aripiprazole—DRD2—lung—esophageal cancer	0.000802	0.00844	CbGeAlD
Aripiprazole—CYP3A5—digestive system—esophageal cancer	0.000781	0.00822	CbGeAlD
Aripiprazole—ADRA2C—lung—esophageal cancer	0.000779	0.0082	CbGeAlD
Aripiprazole—HRH1—digestive system—esophageal cancer	0.000758	0.00798	CbGeAlD
Aripiprazole—HTR2A—trachea—esophageal cancer	0.000736	0.00775	CbGeAlD
Aripiprazole—HTR2B—lymph node—esophageal cancer	0.000677	0.00713	CbGeAlD
Aripiprazole—CYP3A5—lung—esophageal cancer	0.000652	0.00687	CbGeAlD
Aripiprazole—HTR2A—digestive system—esophageal cancer	0.000633	0.00667	CbGeAlD
Aripiprazole—HRH1—lung—esophageal cancer	0.000633	0.00667	CbGeAlD
Aripiprazole—ADRA2A—lung—esophageal cancer	0.000622	0.00655	CbGeAlD
Aripiprazole—CYP3A4—digestive system—esophageal cancer	0.000586	0.00617	CbGeAlD
Aripiprazole—CYP2D6—digestive system—esophageal cancer	0.000577	0.00607	CbGeAlD
Aripiprazole—ABCB1—epithelium—esophageal cancer	0.000545	0.00574	CbGeAlD
Aripiprazole—KCNH2—lymph node—esophageal cancer	0.00054	0.00569	CbGeAlD
Aripiprazole—ADRA2C—lymph node—esophageal cancer	0.000533	0.00561	CbGeAlD
Aripiprazole—HTR2A—lung—esophageal cancer	0.000529	0.00557	CbGeAlD
Aripiprazole—ABCB1—trachea—esophageal cancer	0.000482	0.00508	CbGeAlD
Aripiprazole—HRH1—lymph node—esophageal cancer	0.000433	0.00456	CbGeAlD
Aripiprazole—ADRA2A—lymph node—esophageal cancer	0.000425	0.00448	CbGeAlD
Aripiprazole—ABCB1—digestive system—esophageal cancer	0.000415	0.00437	CbGeAlD
Aripiprazole—Immune system disorder—Cisplatin—esophageal cancer	0.000406	0.00105	CcSEcCtD
Aripiprazole—Mediastinal disorder—Cisplatin—esophageal cancer	0.000405	0.00105	CcSEcCtD
Aripiprazole—Angina pectoris—Capecitabine—esophageal cancer	0.000403	0.00104	CcSEcCtD
Aripiprazole—Alopecia—Cisplatin—esophageal cancer	0.000397	0.00103	CcSEcCtD
Aripiprazole—Abdominal discomfort—Capecitabine—esophageal cancer	0.000397	0.00102	CcSEcCtD
Aripiprazole—Hepatic failure—Methotrexate—esophageal cancer	0.000396	0.00102	CcSEcCtD
Aripiprazole—Erythema—Cisplatin—esophageal cancer	0.000391	0.00101	CcSEcCtD
Aripiprazole—Malnutrition—Cisplatin—esophageal cancer	0.000391	0.00101	CcSEcCtD
Aripiprazole—Neutropenia—Capecitabine—esophageal cancer	0.000387	0.001	CcSEcCtD
Aripiprazole—Dysuria—Capecitabine—esophageal cancer	0.000387	0.001	CcSEcCtD
Aripiprazole—Flatulence—Cisplatin—esophageal cancer	0.000385	0.000996	CcSEcCtD
Aripiprazole—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000384	0.000994	CcSEcCtD
Aripiprazole—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000378	0.000976	CcSEcCtD
Aripiprazole—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000378	0.000976	CcSEcCtD
Aripiprazole—Weight increased—Capecitabine—esophageal cancer	0.000376	0.000973	CcSEcCtD
Aripiprazole—Visual disturbance—Methotrexate—esophageal cancer	0.000376	0.000972	CcSEcCtD
Aripiprazole—Muscle spasms—Cisplatin—esophageal cancer	0.000376	0.000972	CcSEcCtD
Aripiprazole—Weight decreased—Capecitabine—esophageal cancer	0.000374	0.000967	CcSEcCtD
Aripiprazole—Hyperglycaemia—Capecitabine—esophageal cancer	0.000373	0.000964	CcSEcCtD
Aripiprazole—Pneumonia—Capecitabine—esophageal cancer	0.000371	0.000959	CcSEcCtD
Aripiprazole—Infestation NOS—Capecitabine—esophageal cancer	0.000369	0.000953	CcSEcCtD
Aripiprazole—Infestation—Capecitabine—esophageal cancer	0.000369	0.000953	CcSEcCtD
Aripiprazole—Vision blurred—Cisplatin—esophageal cancer	0.000368	0.000952	CcSEcCtD
Aripiprazole—Depression—Capecitabine—esophageal cancer	0.000368	0.00095	CcSEcCtD
Aripiprazole—Tremor—Cisplatin—esophageal cancer	0.000366	0.000947	CcSEcCtD
Aripiprazole—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000364	0.00094	CcSEcCtD
Aripiprazole—Lethargy—Methotrexate—esophageal cancer	0.000364	0.00094	CcSEcCtD
Aripiprazole—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000364	0.00094	CcSEcCtD
Aripiprazole—Ill-defined disorder—Cisplatin—esophageal cancer	0.000363	0.000938	CcSEcCtD
Aripiprazole—Renal failure—Capecitabine—esophageal cancer	0.000363	0.000937	CcSEcCtD
Aripiprazole—Myocardial infarction—Capecitabine—esophageal cancer	0.000362	0.000934	CcSEcCtD
Aripiprazole—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000362	0.000934	CcSEcCtD
Aripiprazole—Anaemia—Cisplatin—esophageal cancer	0.000361	0.000934	CcSEcCtD
Aripiprazole—Stomatitis—Capecitabine—esophageal cancer	0.000359	0.000929	CcSEcCtD
Aripiprazole—Jaundice—Capecitabine—esophageal cancer	0.000359	0.000929	CcSEcCtD
Aripiprazole—Conjunctivitis—Capecitabine—esophageal cancer	0.000358	0.000927	CcSEcCtD
Aripiprazole—Urinary tract infection—Capecitabine—esophageal cancer	0.000358	0.000927	CcSEcCtD
Aripiprazole—Osteoarthritis—Methotrexate—esophageal cancer	0.000356	0.000921	CcSEcCtD
Aripiprazole—Malaise—Cisplatin—esophageal cancer	0.000353	0.000911	CcSEcCtD
Aripiprazole—Haematuria—Capecitabine—esophageal cancer	0.000352	0.000909	CcSEcCtD
Aripiprazole—Leukopenia—Cisplatin—esophageal cancer	0.00035	0.000905	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000349	0.000902	CcSEcCtD
Aripiprazole—Epistaxis—Capecitabine—esophageal cancer	0.000348	0.000899	CcSEcCtD
Aripiprazole—ABCB1—lung—esophageal cancer	0.000346	0.00365	CbGeAlD
Aripiprazole—Agranulocytosis—Capecitabine—esophageal cancer	0.000344	0.00089	CcSEcCtD
Aripiprazole—Irritability—Methotrexate—esophageal cancer	0.00034	0.000879	CcSEcCtD
Aripiprazole—Convulsion—Cisplatin—esophageal cancer	0.000339	0.000876	CcSEcCtD
Aripiprazole—Mood swings—Methotrexate—esophageal cancer	0.000338	0.000872	CcSEcCtD
Aripiprazole—Bradycardia—Capecitabine—esophageal cancer	0.000337	0.000871	CcSEcCtD
Aripiprazole—Ataxia—Methotrexate—esophageal cancer	0.000335	0.000866	CcSEcCtD
Aripiprazole—Myalgia—Cisplatin—esophageal cancer	0.000333	0.00086	CcSEcCtD
Aripiprazole—Haemoglobin—Capecitabine—esophageal cancer	0.000333	0.00086	CcSEcCtD
Aripiprazole—Rhinitis—Capecitabine—esophageal cancer	0.000332	0.000858	CcSEcCtD
Aripiprazole—Anxiety—Cisplatin—esophageal cancer	0.000332	0.000857	CcSEcCtD
Aripiprazole—Hepatitis—Capecitabine—esophageal cancer	0.000331	0.000856	CcSEcCtD
Aripiprazole—Haemorrhage—Capecitabine—esophageal cancer	0.000331	0.000856	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000331	0.000854	CcSEcCtD
Aripiprazole—Hypoaesthesia—Capecitabine—esophageal cancer	0.000329	0.000851	CcSEcCtD
Aripiprazole—Liver function test abnormal—Methotrexate—esophageal cancer	0.000329	0.00085	CcSEcCtD
Aripiprazole—Discomfort—Cisplatin—esophageal cancer	0.000329	0.00085	CcSEcCtD
Aripiprazole—Pharyngitis—Capecitabine—esophageal cancer	0.000329	0.000849	CcSEcCtD
Aripiprazole—Urinary tract disorder—Capecitabine—esophageal cancer	0.000327	0.000845	CcSEcCtD
Aripiprazole—Oedema peripheral—Capecitabine—esophageal cancer	0.000326	0.000843	CcSEcCtD
Aripiprazole—Connective tissue disorder—Capecitabine—esophageal cancer	0.000325	0.000841	CcSEcCtD
Aripiprazole—Urethral disorder—Capecitabine—esophageal cancer	0.000325	0.000839	CcSEcCtD
Aripiprazole—Breast disorder—Methotrexate—esophageal cancer	0.000322	0.000832	CcSEcCtD
Aripiprazole—Anaphylactic shock—Cisplatin—esophageal cancer	0.000319	0.000825	CcSEcCtD
Aripiprazole—Oedema—Cisplatin—esophageal cancer	0.000319	0.000825	CcSEcCtD
Aripiprazole—Visual impairment—Capecitabine—esophageal cancer	0.000319	0.000825	CcSEcCtD
Aripiprazole—Infection—Cisplatin—esophageal cancer	0.000317	0.000819	CcSEcCtD
Aripiprazole—Nervous system disorder—Cisplatin—esophageal cancer	0.000313	0.000809	CcSEcCtD
Aripiprazole—Thrombocytopenia—Cisplatin—esophageal cancer	0.000312	0.000808	CcSEcCtD
Aripiprazole—Tachycardia—Cisplatin—esophageal cancer	0.000311	0.000805	CcSEcCtD
Aripiprazole—Skin disorder—Cisplatin—esophageal cancer	0.00031	0.000801	CcSEcCtD
Aripiprazole—Eye disorder—Capecitabine—esophageal cancer	0.000309	0.0008	CcSEcCtD
Aripiprazole—Tinnitus—Capecitabine—esophageal cancer	0.000309	0.000798	CcSEcCtD
Aripiprazole—Hyperhidrosis—Cisplatin—esophageal cancer	0.000308	0.000797	CcSEcCtD
Aripiprazole—Asthma—Methotrexate—esophageal cancer	0.000308	0.000796	CcSEcCtD
Aripiprazole—Flushing—Capecitabine—esophageal cancer	0.000307	0.000794	CcSEcCtD
Aripiprazole—Cardiac disorder—Capecitabine—esophageal cancer	0.000307	0.000794	CcSEcCtD
Aripiprazole—Eosinophilia—Methotrexate—esophageal cancer	0.000305	0.000788	CcSEcCtD
Aripiprazole—Anorexia—Cisplatin—esophageal cancer	0.000304	0.000786	CcSEcCtD
Aripiprazole—Pancreatitis—Methotrexate—esophageal cancer	0.000302	0.00078	CcSEcCtD
Aripiprazole—Angiopathy—Capecitabine—esophageal cancer	0.0003	0.000776	CcSEcCtD
Aripiprazole—Immune system disorder—Capecitabine—esophageal cancer	0.000299	0.000773	CcSEcCtD
Aripiprazole—Mediastinal disorder—Capecitabine—esophageal cancer	0.000298	0.000771	CcSEcCtD
Aripiprazole—Hypotension—Cisplatin—esophageal cancer	0.000298	0.000771	CcSEcCtD
Aripiprazole—Chills—Capecitabine—esophageal cancer	0.000297	0.000768	CcSEcCtD
Aripiprazole—Abdominal discomfort—Methotrexate—esophageal cancer	0.000295	0.000763	CcSEcCtD
Aripiprazole—Alopecia—Capecitabine—esophageal cancer	0.000293	0.000756	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000291	0.000751	CcSEcCtD
Aripiprazole—Mental disorder—Capecitabine—esophageal cancer	0.00029	0.00075	CcSEcCtD
Aripiprazole—Erythema—Capecitabine—esophageal cancer	0.000288	0.000745	CcSEcCtD
Aripiprazole—Malnutrition—Capecitabine—esophageal cancer	0.000288	0.000745	CcSEcCtD
Aripiprazole—Dysuria—Methotrexate—esophageal cancer	0.000288	0.000744	CcSEcCtD
Aripiprazole—Neutropenia—Methotrexate—esophageal cancer	0.000288	0.000744	CcSEcCtD
Aripiprazole—Paraesthesia—Cisplatin—esophageal cancer	0.000287	0.000741	CcSEcCtD
Aripiprazole—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000286	0.00074	CcSEcCtD
Aripiprazole—Dyspnoea—Cisplatin—esophageal cancer	0.000284	0.000735	CcSEcCtD
Aripiprazole—Flatulence—Capecitabine—esophageal cancer	0.000284	0.000734	CcSEcCtD
Aripiprazole—Erectile dysfunction—Methotrexate—esophageal cancer	0.000284	0.000733	CcSEcCtD
Aripiprazole—Dysgeusia—Capecitabine—esophageal cancer	0.000282	0.000729	CcSEcCtD
Aripiprazole—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000281	0.000726	CcSEcCtD
Aripiprazole—Back pain—Capecitabine—esophageal cancer	0.000279	0.000721	CcSEcCtD
Aripiprazole—Decreased appetite—Cisplatin—esophageal cancer	0.000277	0.000717	CcSEcCtD
Aripiprazole—Muscle spasms—Capecitabine—esophageal cancer	0.000277	0.000716	CcSEcCtD
Aripiprazole—Pneumonia—Methotrexate—esophageal cancer	0.000276	0.000714	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000275	0.000712	CcSEcCtD
Aripiprazole—Infestation NOS—Methotrexate—esophageal cancer	0.000275	0.00071	CcSEcCtD
Aripiprazole—Infestation—Methotrexate—esophageal cancer	0.000275	0.00071	CcSEcCtD
Aripiprazole—Depression—Methotrexate—esophageal cancer	0.000274	0.000708	CcSEcCtD
Aripiprazole—Pain—Cisplatin—esophageal cancer	0.000273	0.000705	CcSEcCtD
Aripiprazole—Vision blurred—Capecitabine—esophageal cancer	0.000272	0.000702	CcSEcCtD
Aripiprazole—Tremor—Capecitabine—esophageal cancer	0.00027	0.000698	CcSEcCtD
Aripiprazole—Renal failure—Methotrexate—esophageal cancer	0.00027	0.000698	CcSEcCtD
Aripiprazole—Stomatitis—Methotrexate—esophageal cancer	0.000268	0.000692	CcSEcCtD
Aripiprazole—Ill-defined disorder—Capecitabine—esophageal cancer	0.000267	0.000691	CcSEcCtD
Aripiprazole—Conjunctivitis—Methotrexate—esophageal cancer	0.000267	0.00069	CcSEcCtD
Aripiprazole—Anaemia—Capecitabine—esophageal cancer	0.000266	0.000688	CcSEcCtD
Aripiprazole—Sweating—Methotrexate—esophageal cancer	0.000263	0.00068	CcSEcCtD
Aripiprazole—Feeling abnormal—Cisplatin—esophageal cancer	0.000263	0.00068	CcSEcCtD
Aripiprazole—Haematuria—Methotrexate—esophageal cancer	0.000262	0.000677	CcSEcCtD
Aripiprazole—Malaise—Capecitabine—esophageal cancer	0.00026	0.000672	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00026	0.000671	CcSEcCtD
Aripiprazole—Epistaxis—Methotrexate—esophageal cancer	0.000259	0.000669	CcSEcCtD
Aripiprazole—Vertigo—Capecitabine—esophageal cancer	0.000259	0.000669	CcSEcCtD
Aripiprazole—Syncope—Capecitabine—esophageal cancer	0.000258	0.000668	CcSEcCtD
Aripiprazole—Leukopenia—Capecitabine—esophageal cancer	0.000258	0.000667	CcSEcCtD
Aripiprazole—Agranulocytosis—Methotrexate—esophageal cancer	0.000256	0.000662	CcSEcCtD
Aripiprazole—Palpitations—Capecitabine—esophageal cancer	0.000255	0.000658	CcSEcCtD
Aripiprazole—Loss of consciousness—Capecitabine—esophageal cancer	0.000253	0.000655	CcSEcCtD
Aripiprazole—Body temperature increased—Cisplatin—esophageal cancer	0.000252	0.000652	CcSEcCtD
Aripiprazole—Cough—Capecitabine—esophageal cancer	0.000252	0.00065	CcSEcCtD
Aripiprazole—Hypertension—Capecitabine—esophageal cancer	0.000249	0.000643	CcSEcCtD
Aripiprazole—Haemoglobin—Methotrexate—esophageal cancer	0.000248	0.00064	CcSEcCtD
Aripiprazole—Hepatitis—Methotrexate—esophageal cancer	0.000246	0.000637	CcSEcCtD
Aripiprazole—Haemorrhage—Methotrexate—esophageal cancer	0.000246	0.000637	CcSEcCtD
Aripiprazole—Arthralgia—Capecitabine—esophageal cancer	0.000245	0.000634	CcSEcCtD
Aripiprazole—Chest pain—Capecitabine—esophageal cancer	0.000245	0.000634	CcSEcCtD
Aripiprazole—Myalgia—Capecitabine—esophageal cancer	0.000245	0.000634	CcSEcCtD
Aripiprazole—Pharyngitis—Methotrexate—esophageal cancer	0.000245	0.000632	CcSEcCtD
Aripiprazole—Anxiety—Capecitabine—esophageal cancer	0.000245	0.000632	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000244	0.00063	CcSEcCtD
Aripiprazole—Urinary tract disorder—Methotrexate—esophageal cancer	0.000243	0.000629	CcSEcCtD
Aripiprazole—Discomfort—Capecitabine—esophageal cancer	0.000242	0.000627	CcSEcCtD
Aripiprazole—Urethral disorder—Methotrexate—esophageal cancer	0.000242	0.000624	CcSEcCtD
Aripiprazole—Dry mouth—Capecitabine—esophageal cancer	0.00024	0.00062	CcSEcCtD
Aripiprazole—Visual impairment—Methotrexate—esophageal cancer	0.000238	0.000614	CcSEcCtD
Aripiprazole—Confusional state—Capecitabine—esophageal cancer	0.000237	0.000613	CcSEcCtD
Aripiprazole—ABCB1—lymph node—esophageal cancer	0.000237	0.00249	CbGeAlD
Aripiprazole—Oedema—Capecitabine—esophageal cancer	0.000235	0.000608	CcSEcCtD
Aripiprazole—Hypersensitivity—Cisplatin—esophageal cancer	0.000235	0.000608	CcSEcCtD
Aripiprazole—Infection—Capecitabine—esophageal cancer	0.000234	0.000604	CcSEcCtD
Aripiprazole—Shock—Capecitabine—esophageal cancer	0.000231	0.000598	CcSEcCtD
Aripiprazole—Nervous system disorder—Capecitabine—esophageal cancer	0.000231	0.000596	CcSEcCtD
Aripiprazole—Eye disorder—Methotrexate—esophageal cancer	0.00023	0.000595	CcSEcCtD
Aripiprazole—Thrombocytopenia—Capecitabine—esophageal cancer	0.00023	0.000595	CcSEcCtD
Aripiprazole—Tinnitus—Methotrexate—esophageal cancer	0.00023	0.000594	CcSEcCtD
Aripiprazole—Tachycardia—Capecitabine—esophageal cancer	0.00023	0.000593	CcSEcCtD
Aripiprazole—Asthenia—Cisplatin—esophageal cancer	0.000229	0.000592	CcSEcCtD
Aripiprazole—Cardiac disorder—Methotrexate—esophageal cancer	0.000229	0.000591	CcSEcCtD
Aripiprazole—Skin disorder—Capecitabine—esophageal cancer	0.000228	0.000591	CcSEcCtD
Aripiprazole—Hyperhidrosis—Capecitabine—esophageal cancer	0.000227	0.000588	CcSEcCtD
Aripiprazole—Anorexia—Capecitabine—esophageal cancer	0.000224	0.00058	CcSEcCtD
Aripiprazole—Angiopathy—Methotrexate—esophageal cancer	0.000224	0.000578	CcSEcCtD
Aripiprazole—Immune system disorder—Methotrexate—esophageal cancer	0.000223	0.000575	CcSEcCtD
Aripiprazole—Mediastinal disorder—Methotrexate—esophageal cancer	0.000222	0.000574	CcSEcCtD
Aripiprazole—Chills—Methotrexate—esophageal cancer	0.000221	0.000572	CcSEcCtD
Aripiprazole—Hypotension—Capecitabine—esophageal cancer	0.00022	0.000568	CcSEcCtD
Aripiprazole—Diarrhoea—Cisplatin—esophageal cancer	0.000218	0.000564	CcSEcCtD
Aripiprazole—Alopecia—Methotrexate—esophageal cancer	0.000218	0.000563	CcSEcCtD
Aripiprazole—Mental disorder—Methotrexate—esophageal cancer	0.000216	0.000558	CcSEcCtD
Aripiprazole—Malnutrition—Methotrexate—esophageal cancer	0.000215	0.000555	CcSEcCtD
Aripiprazole—Erythema—Methotrexate—esophageal cancer	0.000215	0.000555	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000214	0.000554	CcSEcCtD
Aripiprazole—Insomnia—Capecitabine—esophageal cancer	0.000213	0.00055	CcSEcCtD
Aripiprazole—Paraesthesia—Capecitabine—esophageal cancer	0.000211	0.000546	CcSEcCtD
Aripiprazole—Dysgeusia—Methotrexate—esophageal cancer	0.00021	0.000543	CcSEcCtD
Aripiprazole—Dyspnoea—Capecitabine—esophageal cancer	0.00021	0.000542	CcSEcCtD
Aripiprazole—Back pain—Methotrexate—esophageal cancer	0.000208	0.000536	CcSEcCtD
Aripiprazole—Dyspepsia—Capecitabine—esophageal cancer	0.000207	0.000535	CcSEcCtD
Aripiprazole—Decreased appetite—Capecitabine—esophageal cancer	0.000204	0.000528	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000203	0.000525	CcSEcCtD
Aripiprazole—Vomiting—Cisplatin—esophageal cancer	0.000203	0.000524	CcSEcCtD
Aripiprazole—Fatigue—Capecitabine—esophageal cancer	0.000203	0.000524	CcSEcCtD
Aripiprazole—Vision blurred—Methotrexate—esophageal cancer	0.000202	0.000523	CcSEcCtD
Aripiprazole—Rash—Cisplatin—esophageal cancer	0.000201	0.00052	CcSEcCtD
Aripiprazole—Pain—Capecitabine—esophageal cancer	0.000201	0.00052	CcSEcCtD
Aripiprazole—Constipation—Capecitabine—esophageal cancer	0.000201	0.00052	CcSEcCtD
Aripiprazole—Dermatitis—Cisplatin—esophageal cancer	0.000201	0.00052	CcSEcCtD
Aripiprazole—Ill-defined disorder—Methotrexate—esophageal cancer	0.000199	0.000515	CcSEcCtD
Aripiprazole—Anaemia—Methotrexate—esophageal cancer	0.000198	0.000513	CcSEcCtD
Aripiprazole—Feeling abnormal—Capecitabine—esophageal cancer	0.000194	0.000501	CcSEcCtD
Aripiprazole—Malaise—Methotrexate—esophageal cancer	0.000193	0.0005	CcSEcCtD
Aripiprazole—Vertigo—Methotrexate—esophageal cancer	0.000193	0.000498	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000192	0.000497	CcSEcCtD
Aripiprazole—Leukopenia—Methotrexate—esophageal cancer	0.000192	0.000496	CcSEcCtD
Aripiprazole—Nausea—Cisplatin—esophageal cancer	0.00019	0.00049	CcSEcCtD
Aripiprazole—Cough—Methotrexate—esophageal cancer	0.000187	0.000484	CcSEcCtD
Aripiprazole—Urticaria—Capecitabine—esophageal cancer	0.000187	0.000483	CcSEcCtD
Aripiprazole—Abdominal pain—Capecitabine—esophageal cancer	0.000186	0.000481	CcSEcCtD
Aripiprazole—Body temperature increased—Capecitabine—esophageal cancer	0.000186	0.000481	CcSEcCtD
Aripiprazole—Convulsion—Methotrexate—esophageal cancer	0.000186	0.00048	CcSEcCtD
Aripiprazole—Arthralgia—Methotrexate—esophageal cancer	0.000183	0.000472	CcSEcCtD
Aripiprazole—Chest pain—Methotrexate—esophageal cancer	0.000183	0.000472	CcSEcCtD
Aripiprazole—Myalgia—Methotrexate—esophageal cancer	0.000183	0.000472	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000181	0.000469	CcSEcCtD
Aripiprazole—Discomfort—Methotrexate—esophageal cancer	0.00018	0.000466	CcSEcCtD
Aripiprazole—Confusional state—Methotrexate—esophageal cancer	0.000177	0.000456	CcSEcCtD
Aripiprazole—Anaphylactic shock—Methotrexate—esophageal cancer	0.000175	0.000453	CcSEcCtD
Aripiprazole—Infection—Methotrexate—esophageal cancer	0.000174	0.00045	CcSEcCtD
Aripiprazole—Hypersensitivity—Capecitabine—esophageal cancer	0.000173	0.000448	CcSEcCtD
Aripiprazole—Nervous system disorder—Methotrexate—esophageal cancer	0.000172	0.000444	CcSEcCtD
Aripiprazole—Thrombocytopenia—Methotrexate—esophageal cancer	0.000171	0.000443	CcSEcCtD
Aripiprazole—Skin disorder—Methotrexate—esophageal cancer	0.00017	0.00044	CcSEcCtD
Aripiprazole—Hyperhidrosis—Methotrexate—esophageal cancer	0.000169	0.000438	CcSEcCtD
Aripiprazole—Asthenia—Capecitabine—esophageal cancer	0.000169	0.000436	CcSEcCtD
Aripiprazole—Anorexia—Methotrexate—esophageal cancer	0.000167	0.000431	CcSEcCtD
Aripiprazole—Pruritus—Capecitabine—esophageal cancer	0.000166	0.00043	CcSEcCtD
Aripiprazole—Hypotension—Methotrexate—esophageal cancer	0.000164	0.000423	CcSEcCtD
Aripiprazole—Diarrhoea—Capecitabine—esophageal cancer	0.000161	0.000416	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00016	0.000412	CcSEcCtD
Aripiprazole—Insomnia—Methotrexate—esophageal cancer	0.000158	0.000409	CcSEcCtD
Aripiprazole—Paraesthesia—Methotrexate—esophageal cancer	0.000157	0.000406	CcSEcCtD
Aripiprazole—Dyspnoea—Methotrexate—esophageal cancer	0.000156	0.000403	CcSEcCtD
Aripiprazole—Somnolence—Methotrexate—esophageal cancer	0.000156	0.000402	CcSEcCtD
Aripiprazole—Dizziness—Capecitabine—esophageal cancer	0.000156	0.000402	CcSEcCtD
Aripiprazole—Dyspepsia—Methotrexate—esophageal cancer	0.000154	0.000398	CcSEcCtD
Aripiprazole—Decreased appetite—Methotrexate—esophageal cancer	0.000152	0.000393	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000151	0.000391	CcSEcCtD
Aripiprazole—Fatigue—Methotrexate—esophageal cancer	0.000151	0.00039	CcSEcCtD
Aripiprazole—Pain—Methotrexate—esophageal cancer	0.00015	0.000387	CcSEcCtD
Aripiprazole—Vomiting—Capecitabine—esophageal cancer	0.00015	0.000387	CcSEcCtD
Aripiprazole—Rash—Capecitabine—esophageal cancer	0.000148	0.000383	CcSEcCtD
Aripiprazole—Dermatitis—Capecitabine—esophageal cancer	0.000148	0.000383	CcSEcCtD
Aripiprazole—Headache—Capecitabine—esophageal cancer	0.000147	0.000381	CcSEcCtD
Aripiprazole—Feeling abnormal—Methotrexate—esophageal cancer	0.000144	0.000373	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000143	0.00037	CcSEcCtD
Aripiprazole—Nausea—Capecitabine—esophageal cancer	0.00014	0.000361	CcSEcCtD
Aripiprazole—Urticaria—Methotrexate—esophageal cancer	0.000139	0.00036	CcSEcCtD
Aripiprazole—Abdominal pain—Methotrexate—esophageal cancer	0.000138	0.000358	CcSEcCtD
Aripiprazole—Body temperature increased—Methotrexate—esophageal cancer	0.000138	0.000358	CcSEcCtD
Aripiprazole—Hypersensitivity—Methotrexate—esophageal cancer	0.000129	0.000333	CcSEcCtD
Aripiprazole—Asthenia—Methotrexate—esophageal cancer	0.000126	0.000325	CcSEcCtD
Aripiprazole—Pruritus—Methotrexate—esophageal cancer	0.000124	0.00032	CcSEcCtD
Aripiprazole—Diarrhoea—Methotrexate—esophageal cancer	0.00012	0.00031	CcSEcCtD
Aripiprazole—Dizziness—Methotrexate—esophageal cancer	0.000116	0.000299	CcSEcCtD
Aripiprazole—Vomiting—Methotrexate—esophageal cancer	0.000111	0.000288	CcSEcCtD
Aripiprazole—Rash—Methotrexate—esophageal cancer	0.00011	0.000285	CcSEcCtD
Aripiprazole—Dermatitis—Methotrexate—esophageal cancer	0.00011	0.000285	CcSEcCtD
Aripiprazole—Headache—Methotrexate—esophageal cancer	0.00011	0.000284	CcSEcCtD
Aripiprazole—Nausea—Methotrexate—esophageal cancer	0.000104	0.000269	CcSEcCtD
Aripiprazole—DRD4—Signaling Pathways—EP300—esophageal cancer	9.66e-06	3.94e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CREBBP—esophageal cancer	9.64e-06	3.93e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—ERBB2—esophageal cancer	9.61e-06	3.92e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—CDKN1A—esophageal cancer	9.59e-06	3.91e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—EP300—esophageal cancer	9.53e-06	3.88e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—ERBB2—esophageal cancer	9.52e-06	3.88e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	9.52e-06	3.88e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—NOS3—esophageal cancer	9.51e-06	3.88e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	9.48e-06	3.87e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—EGFR—esophageal cancer	9.47e-06	3.86e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CREBBP—esophageal cancer	9.46e-06	3.86e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—CREBBP—esophageal cancer	9.46e-06	3.85e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—CCND1—esophageal cancer	9.45e-06	3.85e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CREBBP—esophageal cancer	9.43e-06	3.84e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CREBBP—esophageal cancer	9.4e-06	3.83e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ENO1—esophageal cancer	9.39e-06	3.83e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PTGS1—esophageal cancer	9.39e-06	3.83e-05	CbGpPWpGaD
Aripiprazole—DRD5—Signaling Pathways—TP53—esophageal cancer	9.36e-06	3.82e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	9.36e-06	3.82e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—NOS3—esophageal cancer	9.36e-06	3.81e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—CCND1—esophageal cancer	9.32e-06	3.8e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	9.32e-06	3.8e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	9.31e-06	3.8e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CREBBP—esophageal cancer	9.31e-06	3.8e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—EGFR—esophageal cancer	9.3e-06	3.79e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	9.29e-06	3.78e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—EGFR—esophageal cancer	9.27e-06	3.78e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PSME1—esophageal cancer	9.26e-06	3.77e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PSME2—esophageal cancer	9.26e-06	3.77e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—EGFR—esophageal cancer	9.24e-06	3.77e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—NOS3—esophageal cancer	9.24e-06	3.77e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—EP300—esophageal cancer	9.22e-06	3.76e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—PTGS2—esophageal cancer	9.21e-06	3.75e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	9.19e-06	3.75e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—EGFR—esophageal cancer	9.15e-06	3.73e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	9.15e-06	3.73e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—CDKN1A—esophageal cancer	9.14e-06	3.72e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	9.13e-06	3.72e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—EP300—esophageal cancer	9.12e-06	3.72e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling by GPCR—PIK3CA—esophageal cancer	9.06e-06	3.69e-05	CbGpPWpGaD
Aripiprazole—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	9.05e-06	3.69e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—CDKN1A—esophageal cancer	9.02e-06	3.67e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling by GPCR—PIK3CA—esophageal cancer	8.92e-06	3.63e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—EP300—esophageal cancer	8.91e-06	3.63e-05	CbGpPWpGaD
Aripiprazole—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	8.91e-06	3.63e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—ERBB2—esophageal cancer	8.9e-06	3.63e-05	CbGpPWpGaD
Aripiprazole—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	8.89e-06	3.62e-05	CbGpPWpGaD
Aripiprazole—CHRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	8.86e-06	3.61e-05	CbGpPWpGaD
Aripiprazole—CHRM3—GPCR downstream signaling—PIK3CA—esophageal cancer	8.83e-06	3.6e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—MYC—esophageal cancer	8.8e-06	3.59e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—MYC—esophageal cancer	8.79e-06	3.58e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—ERBB2—esophageal cancer	8.76e-06	3.57e-05	CbGpPWpGaD
Aripiprazole—CHRM2—GPCR downstream signaling—PIK3CA—esophageal cancer	8.75e-06	3.56e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—MYC—esophageal cancer	8.73e-06	3.56e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	8.72e-06	3.55e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—EP300—esophageal cancer	8.69e-06	3.54e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—EP300—esophageal cancer	8.65e-06	3.53e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—NOS3—esophageal cancer	8.63e-06	3.52e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	8.63e-06	3.52e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—EGFR—esophageal cancer	8.61e-06	3.51e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—EGFR—esophageal cancer	8.6e-06	3.5e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—EP300—esophageal cancer	8.58e-06	3.5e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—MYC—esophageal cancer	8.55e-06	3.49e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—EGFR—esophageal cancer	8.54e-06	3.48e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—CCND1—esophageal cancer	8.49e-06	3.46e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—NOS3—esophageal cancer	8.49e-06	3.46e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	8.48e-06	3.46e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—NOS3—esophageal cancer	8.47e-06	3.45e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—NOS3—esophageal cancer	8.47e-06	3.45e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—PTGS2—esophageal cancer	8.45e-06	3.44e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—NOS3—esophageal cancer	8.45e-06	3.44e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—NOS3—esophageal cancer	8.42e-06	3.43e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—MYC—esophageal cancer	8.42e-06	3.43e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—CCND1—esophageal cancer	8.41e-06	3.43e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—EGFR—esophageal cancer	8.37e-06	3.41e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—NOS3—esophageal cancer	8.34e-06	3.4e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	8.31e-06	3.39e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—MYC—esophageal cancer	8.3e-06	3.38e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—EGFR—esophageal cancer	8.23e-06	3.35e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	8.22e-06	3.35e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—CDKN1A—esophageal cancer	8.22e-06	3.35e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—CDKN1A—esophageal cancer	8.14e-06	3.32e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—CCND1—esophageal cancer	8.12e-06	3.31e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—EGFR—esophageal cancer	8.12e-06	3.31e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	8.1e-06	3.3e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	8.09e-06	3.3e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—CCND1—esophageal cancer	8.08e-06	3.29e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—ERBB2—esophageal cancer	8.07e-06	3.29e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	8.07e-06	3.29e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—PIK3CA—esophageal cancer	8.05e-06	3.28e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—MYC—esophageal cancer	8.03e-06	3.27e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—PIK3CA—esophageal cancer	8.02e-06	3.27e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CYP1B1—esophageal cancer	7.99e-06	3.26e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—MYC—esophageal cancer	7.95e-06	3.24e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	7.94e-06	3.24e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—PIK3CA—esophageal cancer	7.94e-06	3.24e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—ERBB2—esophageal cancer	7.93e-06	3.23e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	7.92e-06	3.23e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—ERBB2—esophageal cancer	7.9e-06	3.22e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—ERBB2—esophageal cancer	7.88e-06	3.21e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—CCND1—esophageal cancer	7.86e-06	3.2e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—EGFR—esophageal cancer	7.86e-06	3.2e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	7.86e-06	3.2e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	7.82e-06	3.19e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—EP300—esophageal cancer	7.82e-06	3.19e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—ERBB2—esophageal cancer	7.8e-06	3.18e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—EGFR—esophageal cancer	7.78e-06	3.17e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	7.78e-06	3.17e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—EP300—esophageal cancer	7.75e-06	3.16e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PTGS2—esophageal cancer	7.74e-06	3.16e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CCND1—esophageal cancer	7.74e-06	3.15e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	7.73e-06	3.15e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—EP300—esophageal cancer	7.66e-06	3.12e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—CDKN1A—esophageal cancer	7.6e-06	3.1e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—MYC—esophageal cancer	7.58e-06	3.09e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CYP19A1—esophageal cancer	7.51e-06	3.06e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—CDKN1A—esophageal cancer	7.48e-06	3.05e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—EP300—esophageal cancer	7.48e-06	3.05e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—MYC—esophageal cancer	7.48e-06	3.05e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—PIK3CA—esophageal cancer	7.47e-06	3.05e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—PIK3CA—esophageal cancer	7.46e-06	3.04e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—EP300—esophageal cancer	7.44e-06	3.03e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—PIK3CA—esophageal cancer	7.42e-06	3.02e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—EGFR—esophageal cancer	7.41e-06	3.02e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	7.36e-06	3e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—EGFR—esophageal cancer	7.31e-06	2.98e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—PIK3CA—esophageal cancer	7.26e-06	2.96e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—EP300—esophageal cancer	7.23e-06	2.95e-05	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—TP53—esophageal cancer	7.23e-06	2.95e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	7.23e-06	2.94e-05	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—TP53—esophageal cancer	7.22e-06	2.94e-05	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—TP53—esophageal cancer	7.17e-06	2.92e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—PIK3CA—esophageal cancer	7.14e-06	2.91e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—CREBBP—esophageal cancer	7.14e-06	2.91e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CCND1—esophageal cancer	7.13e-06	2.91e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—EP300—esophageal cancer	7.12e-06	2.9e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—PIK3CA—esophageal cancer	7.05e-06	2.87e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—EP300—esophageal cancer	7.03e-06	2.86e-05	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—TP53—esophageal cancer	7.02e-06	2.86e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CCND1—esophageal cancer	7.02e-06	2.86e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CCND1—esophageal cancer	7e-06	2.85e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CCND1—esophageal cancer	6.98e-06	2.84e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CCND1—esophageal cancer	6.96e-06	2.84e-05	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—TP53—esophageal cancer	6.91e-06	2.82e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	6.9e-06	2.81e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CCND1—esophageal cancer	6.89e-06	2.81e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	6.87e-06	2.8e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—HMOX1—esophageal cancer	6.85e-06	2.79e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—PIK3CA—esophageal cancer	6.82e-06	2.78e-05	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—TP53—esophageal cancer	6.82e-06	2.78e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—MYC—esophageal cancer	6.81e-06	2.78e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	6.79e-06	2.77e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	6.77e-06	2.76e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CDKN1A—esophageal cancer	6.75e-06	2.75e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—PIK3CA—esophageal cancer	6.75e-06	2.75e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—MYC—esophageal cancer	6.75e-06	2.75e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CDKN1A—esophageal cancer	6.73e-06	2.74e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—CREBBP—esophageal cancer	6.72e-06	2.74e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CDKN1A—esophageal cancer	6.67e-06	2.72e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—EGFR—esophageal cancer	6.66e-06	2.72e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	6.65e-06	2.71e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—EGFR—esophageal cancer	6.6e-06	2.69e-05	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—TP53—esophageal cancer	6.6e-06	2.69e-05	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—PIK3CA—esophageal cancer	6.59e-06	2.69e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ABCB1—esophageal cancer	6.58e-06	2.68e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—EP300—esophageal cancer	6.56e-06	2.68e-05	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—TP53—esophageal cancer	6.53e-06	2.66e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—MYC—esophageal cancer	6.52e-06	2.66e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—MYC—esophageal cancer	6.48e-06	2.64e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—EP300—esophageal cancer	6.46e-06	2.63e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—EP300—esophageal cancer	6.45e-06	2.63e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—EP300—esophageal cancer	6.44e-06	2.62e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—PIK3CA—esophageal cancer	6.43e-06	2.62e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—EP300—esophageal cancer	6.42e-06	2.62e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—EP300—esophageal cancer	6.4e-06	2.61e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—PIK3CA—esophageal cancer	6.4e-06	2.61e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—NOS3—esophageal cancer	6.39e-06	2.6e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	6.38e-06	2.6e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—EGFR—esophageal cancer	6.37e-06	2.6e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—PIK3CA—esophageal cancer	6.35e-06	2.59e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—EP300—esophageal cancer	6.34e-06	2.58e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—EGFR—esophageal cancer	6.34e-06	2.58e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—EP300—esophageal cancer	6.32e-06	2.58e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—MYC—esophageal cancer	6.3e-06	2.57e-05	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—TP53—esophageal cancer	6.22e-06	2.54e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MYC—esophageal cancer	6.2e-06	2.53e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	6.18e-06	2.52e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—EGFR—esophageal cancer	6.17e-06	2.51e-05	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—TP53—esophageal cancer	6.14e-06	2.5e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—EGFR—esophageal cancer	6.07e-06	2.47e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—NOS3—esophageal cancer	6.02e-06	2.45e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—EP300—esophageal cancer	5.88e-06	2.39e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PTGS2—esophageal cancer	5.84e-06	2.38e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—PIK3CA—esophageal cancer	5.78e-06	2.36e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—PIK3CA—esophageal cancer	5.73e-06	2.34e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MYC—esophageal cancer	5.72e-06	2.33e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—PIK3CA—esophageal cancer	5.67e-06	2.31e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MYC—esophageal cancer	5.63e-06	2.29e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MYC—esophageal cancer	5.62e-06	2.29e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MYC—esophageal cancer	5.6e-06	2.28e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—EGFR—esophageal cancer	5.6e-06	2.28e-05	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TP53—esophageal cancer	5.59e-06	2.28e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MYC—esophageal cancer	5.58e-06	2.27e-05	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TP53—esophageal cancer	5.54e-06	2.26e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	5.53e-06	2.25e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MYC—esophageal cancer	5.53e-06	2.25e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MYC—esophageal cancer	5.51e-06	2.25e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PTGS2—esophageal cancer	5.51e-06	2.24e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—EGFR—esophageal cancer	5.51e-06	2.24e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	5.5e-06	2.24e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—EGFR—esophageal cancer	5.49e-06	2.24e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—EGFR—esophageal cancer	5.48e-06	2.23e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—EGFR—esophageal cancer	5.46e-06	2.22e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—EGFR—esophageal cancer	5.41e-06	2.2e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	5.39e-06	2.2e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—PIK3CA—esophageal cancer	5.35e-06	2.18e-05	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TP53—esophageal cancer	5.35e-06	2.18e-05	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TP53—esophageal cancer	5.32e-06	2.17e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—PIK3CA—esophageal cancer	5.27e-06	2.15e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—PIK3CA—esophageal cancer	5.2e-06	2.12e-05	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TP53—esophageal cancer	5.18e-06	2.11e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MYC—esophageal cancer	5.12e-06	2.09e-05	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TP53—esophageal cancer	5.1e-06	2.08e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	5.01e-06	2.04e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—EP300—esophageal cancer	4.86e-06	1.98e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	4.86e-06	1.98e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	4.78e-06	1.95e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	4.77e-06	1.94e-05	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PIK3CA—esophageal cancer	4.76e-06	1.94e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—PIK3CA—esophageal cancer	4.75e-06	1.94e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—PIK3CA—esophageal cancer	4.74e-06	1.93e-05	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TP53—esophageal cancer	4.7e-06	1.91e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—PIK3CA—esophageal cancer	4.69e-06	1.91e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	4.68e-06	1.91e-05	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TP53—esophageal cancer	4.62e-06	1.88e-05	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TP53—esophageal cancer	4.61e-06	1.88e-05	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TP53—esophageal cancer	4.6e-06	1.87e-05	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TP53—esophageal cancer	4.58e-06	1.87e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—EP300—esophageal cancer	4.58e-06	1.87e-05	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TP53—esophageal cancer	4.54e-06	1.85e-05	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TP53—esophageal cancer	4.53e-06	1.84e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CREBBP—esophageal cancer	4.4e-06	1.79e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	4.35e-06	1.77e-05	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TP53—esophageal cancer	4.21e-06	1.71e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—NOS3—esophageal cancer	3.94e-06	1.6e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PTGS2—esophageal cancer	3.6e-06	1.47e-05	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CA—esophageal cancer	3.59e-06	1.47e-05	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CA—esophageal cancer	3.39e-06	1.38e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—EP300—esophageal cancer	2.99e-06	1.22e-05	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.21e-06	9.03e-06	CbGpPWpGaD
